Senores Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals reported strong Q1 FY26 (quarter ended June 30, 2025) consolidated results with total income of Rs. 138 Cr, up 72% year-on-year. EBITDA grew 60% YoY to Rs. 34.2 Cr and profit after tax surged 95% YoY to Rs. 21.2 Cr. Regulated Markets revenue jumped 69% YoY to Rs. 90 Cr while Emerging Markets revenue grew 32% YoY to Rs. 29 Cr. Gross margin stood at 55.5% and EBITDA margin at 24.8%, though slightly compressed from 26.5% a year ago. The company reported positive operating cash flow of Rs. 11 Cr for the quarter. Statutory auditors (Pankaj R. Shah & Associates) issued a clean limited review report with an Emphasis of Matter noting that prior year comparatives (Q1 FY25) were management-compiled and not subject to audit/review, and that tax provisions are management estimates.
Strong YoY revenue and profit growth signals robust business momentum, especially in the higher-margin Regulated Markets segment. The slight EBITDA margin compression YoY is a minor watchpoint, but QoQ margin expansion and positive operating cash flow are positives. IPO proceeds of Rs. 259 Cr remain unutilized (especially Rs. 107 Cr earmarked for Havix's Atlanta sterile injectables facility), which could be a near-term overhang if deployment lags.